Calidi Biotherapeutics, Inc. - CLDI STOCK NEWS

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has completed its previously announced public offering. The company sold 5,000,000 shares of common stock at $0.85 per share, raising gross proceeds of approximately $4.25 million.

Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the offering, which was conducted under an effective Form S-3 registration statement. The final prospectus was filed with the SEC on January 10, 2025, and is available through the SEC's website and Ladenburg Thalmann & Co. Inc.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced the pricing of its public offering of 5,000,000 shares of common stock at $0.85 per share, expecting to raise gross proceeds of approximately $4.25 million. The offering is expected to close on January 10, 2025, with Ladenburg Thalmann & Co. Inc. acting as exclusive placement agent.

The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement on Form S-3, which was declared effective by the SEC on October 10, 2024.

Calidi is a clinical-stage biotechnology company developing targeted immunotherapies, with proprietary technology focused on arming the immune system to fight cancer through stem cell-based platforms carrying oncolytic viruses for multiple oncology indications.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has announced plans for a public offering of common stock and pre-funded warrants. The offering will be conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent.

The company intends to use the proceeds for working capital and general corporate purposes. The securities will be offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, providing detailed information about the offering terms.

Calidi Biotherapeutics presented data at IOVC and SITC conferences showcasing their RTNova™ systemic enveloped virotherapy technology for targeting metastatic lung cancer. The technology utilizes a tumor-selective vaccinia virus engineered to produce extracellular enveloped viruses (EEVs), designed to target multiple metastatic tumor sites while avoiding immune system clearance.

The data demonstrated RTNova's therapeutic potential in an advanced lung metastasis model, both as a monotherapy and as a viral vector for delivering therapeutic payloads. The technology shows promise in killing and transforming tumor microenvironments across multiple sites, potentially offering new treatment options for previously untreatable metastatic diseases.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has completed its previously announced public offering of 4,437,869 shares of common stock. The shares were priced at $1.69 per share, generating gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the offering, which was conducted under an effective Form S-3 registration statement.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced the pricing of its public offering of 4,437,869 shares of common stock at $1.69 per share, expecting to raise approximately $7.5 million in gross proceeds. The offering is expected to close around November 15, 2024. Ladenburg Thalmann & Co. Inc. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials. The offering is being made through a shelf registration statement that was declared effective on October 10, 2024.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company, has announced its intention to conduct a public offering of common stock and pre-funded warrants. The offering will be managed by Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The securities are being offered through a shelf registration statement that was declared effective on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.

Calidi Biotherapeutics (NYSE: CLDI) reported Q3 2024 financial results and key developments. The FDA cleared Northwestern University's IND application for NeuroNova (CLD-101), with Phase 1b/2 clinical trials in high-grade glioma expected to begin in early 2025. The company presented data on RTNova (CLD-400), their systemic antitumor virotherapy platform, at multiple conferences. Financially, Calidi reported a net loss of $5.1 million ($0.65 per share) compared to $2.0 million ($1.41 per share) in Q3 2023. The company raised $2 million through a registered direct offering and had $1.9 million in cash as of September 30, 2024.

Nexalin Technology (Nasdaq:NXL) and Calidi Biotherapeutics will be featured on Bloomberg TV's RedChip Small Stocks, Big Money show on October 26, 2024, at 7 p.m. ET. Nexalin's CEO Mark White will discuss their non-invasive neurostimulation technology for mental health treatment, including the Gen-3 HALO Clarity device, targeting a market projected to reach $537 billion by 2030. The technology addresses conditions like insomnia, PTSD, and traumatic brain injuries. Calidi's Chief Business Officer Stephen Thesing will present their oncolytic virotherapy developments for cancer treatment, featuring both systemic and localized approaches with engineered viruses protected by cell-based technologies.